Hosted on MSN18d
Shuttle Pharmaceuticals expands glioblastoma trial
In addition, Shuttle Pharmaceuticals secured a patent for selective histone deacetylase (HDAC) inhibitors, contributing to its mission to enhance cancer treatments. Moreover, the company faces a ...
Hosted on MSN28d
Shuttle Pharma hits 25% mark in glioblastoma trial
Patients in this study have IDH wild-type, methylation negative glioblastoma ... secured a patent for selective histone deacetylase (HDAC) inhibitors, a noteworthy advancement in its mission ...
Nature6y
Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor
Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...